Hayashi K, Anzai N. Novel therapeutic approaches targeting L-type amino acid transporters for cancer treatment. World J Gastrointest Oncol 2017; 9(1): 21-29 [PMID: 28144396 DOI: 10.4251/wjgo.v9.i1.21]
Corresponding Author of This Article
Keitaro Hayashi, PhD, Associate Professor, Department of Pharmacology and Toxicology, Dokkyo Medical University School of Medicine, 880 Kitakobayashi, Mibu, Shimotsuga, Tochigi 321-0293, Japan. khayashi@dokkyomed.ac.jp
Research Domain of This Article
Oncology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Jan 15, 2017; 9(1): 21-29 Published online Jan 15, 2017. doi: 10.4251/wjgo.v9.i1.21
Novel therapeutic approaches targeting L-type amino acid transporters for cancer treatment
Keitaro Hayashi, Naohiko Anzai
Keitaro Hayashi, Naohiko Anzai, Department of Pharmacology and Toxicology, Dokkyo Medical University School of Medicine, Shimotsuga, Tochigi 321-0293, Japan
Naohiko Anzai, Department of Pharmacology, Chiba University Graduate School of Medicine, Chuo, Chiba 260-8670, Japan
Author contributions: Hayashi K wrote the manuscript; Anzai N reviewed the manuscript.
Conflict-of-interest statement: There is no conflict of interest associated with any of the senior author or other coauthors contributed their efforts in this manuscript.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Keitaro Hayashi, PhD, Associate Professor, Department of Pharmacology and Toxicology, Dokkyo Medical University School of Medicine, 880 Kitakobayashi, Mibu, Shimotsuga, Tochigi 321-0293, Japan. khayashi@dokkyomed.ac.jp
Telephone: +81-282-872128 Fax: +81-282-862915
Received: August 15, 2016 Peer-review started: August 16, 2016 First decision: September 28, 2016 Revised: October 8, 2016 Accepted: November 1, 2016 Article in press: November 2, 2016 Published online: January 15, 2017 Processing time: 149 Days and 23.5 Hours
Abstract
L-type amino acid transporters (LATs) mainly assist the uptake of neutral amino acids into cells. Four LATs (LAT1, LAT2, LAT3 and LAT4) have so far been identified. LAT1 (SLC7A5) has been attracting much attention in the field of cancer research since it is commonly up-regulated in various cancers. Basic research has made it increasingly clear that LAT1 plays a predominant role in malignancy. The functional significance of LAT1 in cancer and the potential therapeutic application of the features of LAT1 to cancer management are described in this review.
Core tip: The discovery of molecules preferentially expressed in cancer cells is extremely valuable for the development of molecular target drugs in cancer therapy. Amino acid transporters have been receiving a great amount of attention as a candidate of such molecular targets. This review summarizes new initiatives for clinical applications of the basic research relative to L-type amino acid transporters, which are commonly expressed in cancers.
